Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
304 participants
OBSERVATIONAL
2012-11-30
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. To investigate the prevalence of symptoms, anxiety, depression, and sleep-disordered breathing within ILD patient population.
3. To assess the economic impact of ILD.
4. To understand how self-aware ILD patients are regarding their treatment/management.
5. To compare the demographic details, including smoking status and occupational history, of patients with interstitial lung disease
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
• Health status in the target populations, as determined by the K-BILD questionnaire.
Secondary endpoints -
* Severity of dyspnoea suffered by patients
* Prevalence of anxiety and depression
* Prevalence of sleep-disordered breathing symptoms
* Degree of self-awareness displayed by patients
* The costs associated with ILD from a patient and healthcare perspective.
* Demographic details
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Idiopathic Pulmonary Fibrosis
Questionnaire evaluation
No interventions assigned to this group
Non Idiopathic Pulmonary Fibrosis
Questionnaire evaluation
No interventions assigned to this group
Sarciodosis
Questionnaire evaluation
No interventions assigned to this group
Healthy Controls
Questionnaire evaluation
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age greater than 18 years of age
* Any smoking status
* Diagnosis of Interstitial Lung Disease as defined below
* Full pulmonary lung function tests and routine immunological tests undertaken within 6 months of entry into study
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of East Anglia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew M Wilson
Role: PRINCIPAL_INVESTIGATOR
University of East Anglia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Norfolk and Norwich Univeristy Hospital NHS foundation Trust
Norwich, Norfolk, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UEAILDQUEST
Identifier Type: OTHER
Identifier Source: secondary_id
2012RESP05
Identifier Type: -
Identifier Source: org_study_id